GO:0035563 positive regulation of chromatin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035563 (positive regulation of chromatin binding) describes any process that increases the frequency, rate or extent of selective interaction with chromatin, the DNA-protein-RNA fiber network of interphase chromosomes.
• This regulatory process is essential for gene expression, cell identity, immune cell function and genome stability, and its disruption is linked to autoimmunity, cancer and neurodevelopmental disorders.
• Key molecular players include transcription factors such as FOXP3 and RUNX3, chromatin-binding proteins such as PHF6, and structural regulators such as type II topoisomerases.
• Experimental dissection of chromatin binding relies on ATAC-seq, RNA-seq, TurboCas locus-specific proteomics, and CRISPR-based perturbation.
• Disease relevance spans regulatory T cell dysfunction in autoimmunity, stress susceptibility in the pituitary, and oncogenic chromatin remodeling in hepatocellular carcinoma.
• CRISPR knockout, point mutation, knock-in and overexpression models enable causal testing of candidate regulators of chromatin binding.
Description
GO:0035563, positive regulation of chromatin binding, is a biological process term that captures any mechanism increasing the selective interaction of proteins or complexes with chromatin, the fibrous network of DNA, protein and sometimes RNA that forms chromosomes during interphase. In practical terms, it answers a central question in molecular biology: what makes a factor find and stay on the right genomic region at the right time? This process underlies transcription factor occupancy, epigenetic marking, DNA repair and chromosome segregation, and it is therefore a recurring theme in studies of development, immunity and cancer. Researchers encounter positive regulation of chromatin binding whenever a signaling pathway, a pioneer factor or a chromatin remodeler enhances the recruitment of another factor to chromatin. For example, an autoimmune transcriptional circuit can alter the chromatin-binding behavior of FOXP3-positive regulatory T cells, and chromatin-binding proteins such as PHF6 can modulate stress susceptibility in the pituitary intermediate lobe. Similarly, RUNX3 programs CD8-positive T cell residency by shaping chromatin interactions in non-lymphoid tissues and tumors. These examples illustrate that positive regulation of chromatin binding is not a single molecular event but a regulatory layer that integrates signaling, transcription and genome architecture. Because the term is defined by an increase in chromatin binding rather than by a specific gene or complex, its study requires quantitative, locus-resolved methods. Modern approaches combine chromatin accessibility mapping, transcriptomics and locus-specific proteomics to determine which factors bind, where and with what consequence. This article synthesizes the QuickGO definition with verified PubMed literature to outline the mechanisms, key genes, disease links and experimental strategies relevant to GO:0035563.
positive regulation of chromatin binding At A Glance
| GO ID | GO:0035563 |
|---|---|
| GO term | positive regulation of chromatin binding |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the frequency, rate or extent of selective interaction with chromatin |
| Definition source | QuickGO definition of GO:0035563 |
| Related process | Chromatin binding (GO:0003682) is the regulated process |
| Biological context | Interphase nucleus; DNA-protein-RNA fiber network of chromosomes |
| Research relevance | Controls transcription factor occupancy, epigenetic marking, immune cell identity and genome stability |
What Is GO:0035563?
Positive regulation of chromatin binding (GO:0035563) is any process that increases the frequency, rate or extent of chromatin binding. Chromatin binding itself is the selective interaction with chromatin, the network of fibers of DNA, protein and sometimes RNA that make up the chromosomes of the eukaryotic nucleus during interphase. In other words, this GO term describes the positive control of how often, how fast or how extensively a molecule engages with chromatin, without specifying the identity of the binder or the genomic location.
Why Is positive regulation of chromatin binding Important in Cell Biology?
Positive regulation of chromatin binding is important because it determines which genomic regions are engaged by regulatory factors and therefore influences gene expression programs, cell fate decisions and genome maintenance. Disruption of this regulatory layer can drive autoimmunity, alter stress responses and promote cancer, making it a focal point for mechanistic studies and therapeutic hypothesis generation.
• Controls transcription factor occupancy and gene expression programs in immune cells.
• Shapes regulatory T cell function and autoimmune transcriptional circuits.
• Modulates stress susceptibility through chromatin-binding proteins in the pituitary.
• Programs CD8-positive T cell residency in non-lymphoid tissues and tumors.
• Influences 3D chromatin folding through type II topoisomerase activity.
• Regulates T cell quiescence and exhaustion via LINE1 splicing and chromatin interactions.
• Contributes to oncogenic chromatin remodeling in hepatocellular carcinoma.
• Is required for meiotic recombination and prevents inappropriate RAD51/DMC1 loading.
• Provides a mechanistic entry point for CRISPR-based functional genomics.
• Enables locus-specific proteomic interrogation of chromatin-associated complexes.
What Happens During positive regulation of chromatin binding?
Initiation by pioneer and signaling factors
In simple terms: First, certain proteins open the door so others can bind chromatin.
Positive regulation of chromatin binding often begins when pioneer transcription factors or signaling-responsive proteins increase chromatin accessibility or create a permissive local environment. In autoimmune settings, an altered transcriptional circuit can change the chromatin-binding behavior of FOXP3-positive regulatory T cells, effectively increasing or redirecting their engagement with chromatin. Similarly, RUNX3 acts as a programming factor that promotes CD8-positive T cell residency by shaping chromatin interactions in non-lymphoid tissues and tumors. These initiating events are not passive; they reflect active regulation that raises the probability of subsequent chromatin binding.
Enhancement of chromatin association
In simple terms: Next, the process boosts how often and how strongly a factor sticks to chromatin.
Once a permissive state is established, positive regulation can increase the frequency, rate or extent of chromatin binding by stabilizing factor-chromatin contacts. Chromatin-binding proteins such as PHF6 illustrate this principle: PHF6 regulates stress susceptibility in the pituitary intermediate lobe, indicating that its chromatin engagement is subject to positive control. At a structural level, type II topoisomerases shape multi-scale 3D chromatin folding in regions of positive supercoils, providing a physical mechanism by which chromatin architecture can favor or constrain binding events. Thus, enhancement of chromatin association is both a biochemical and a topological phenomenon.
Locus-specific assembly and proteomic remodeling
In simple terms: Then, specific genomic regions recruit their own set of proteins.
Positive regulation of chromatin binding is frequently locus-specific, meaning that particular genomic regions assemble distinct protein interactomes. TurboCas enables locus-specific labeling of genomic regions and isolation of their associated protein interactome, allowing researchers to capture which factors are recruited to a given site. This approach has revealed that chromatin-associated complexes are dynamically remodeled, and that positive regulation can be measured as an increase in the abundance or diversity of proteins at a locus. Such locus-resolved data are essential for moving beyond correlative chromatin accessibility to causal interaction maps.
Integration with transcription and genome stability
In simple terms: Finally, the process is coupled to gene expression and chromosome maintenance.
Increased chromatin binding is functionally coupled to transcription and genome stability. Integrative analysis based on ATAC-seq and RNA-seq has identified PRPF3 as a novel oncogene in hepatocellular carcinoma, linking chromatin accessibility changes to transcriptional output. In meiosis, FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading, demonstrating that positive regulation of chromatin binding must be tightly controlled to avoid inappropriate recombination. LINE1 splicing in non-canonical transcript variants regulates T cell quiescence and exhaustion, further connecting chromatin binding to cell-state transitions. Together, these examples show that positive regulation of chromatin binding integrates transcription, recombination and cell fate.
Key Genes Involved in GO:0035563 positive regulation of chromatin binding
The following genes and proteins have been experimentally implicated in processes that increase or modulate chromatin binding, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FOXP3 | Regulatory T cell transcription factor | Autoimmune transcriptional circuit and Treg dysfunction |
| PHF6 | Chromatin-binding protein | Stress susceptibility in pituitary intermediate lobe |
| RUNX3 | Transcription factor programming T cell residency | CD8-positive T cell residency in tissues and tumors |
| PRPF3 | Oncogene linked to chromatin accessibility | Hepatocellular carcinoma integrative analysis |
| TOP2A | Type II topoisomerase | Shapes 3D chromatin folding in positive supercoil regions |
| TOP2B | Type II topoisomerase | Multi-scale 3D chromatin folding |
| LINE1 | Retrotransposon-derived transcript | T cell quiescence and exhaustion regulation |
| FIGNL1 | Meiotic recombination regulator | Prevents inappropriate RAD51/DMC1 loading |
| FIRRM | FIGNL1-interacting protein | Essential for meiotic recombination |
| RAD51 | Recombinase | DNA damage-independent loading control |
| DMC1 | Meiotic recombinase | Prevents inappropriate loading during meiosis |
| FOXP3-positive Tregs | Cell population | Autoimmune circuit and chromatin binding |
| CD8-positive T cells | Cell population | Tissue residency programming |
| Hepatocellular carcinoma cells | Cancer model | PRPF3 oncogene and chromatin accessibility |
| Pituitary intermediate lobe cells | Neuroendocrine model | PHF6 stress susceptibility |
| Meiotic germ cells | Developmental model | FIGNL1-FIRRM recombination control |
| T cell exhaustion models | Immunology model | LINE1 splicing and quiescence |
How Is positive regulation of chromatin binding Regulated?
Positive regulation of chromatin binding is itself regulated at multiple levels. Signaling pathways and transcriptional circuits can alter the expression or activity of chromatin-binding proteins, as seen in autoimmune transcriptional circuits that drive FOXP3-positive regulatory T cell dysfunction. Chromatin topology, including positive supercoils shaped by type II topoisomerases, can constrain or facilitate binding events. In addition, splicing and non-canonical transcript variants of LINE1 regulate T cell quiescence and exhaustion, indicating that post-transcriptional mechanisms feed into chromatin-binding regulation. Finally, meiotic recombination factors such as FIGNL1-FIRRM prevent inappropriate RAD51 and DMC1 loading, showing that negative constraints are essential to keep positive regulation within physiological bounds.
positive regulation of chromatin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FOXP3 | Autoimmune regulatory T cell dysfunction | Knockout or point-mutation Treg models |
| PHF6 | Stress susceptibility in pituitary | Knockout or overexpression in pituitary cells |
| PRPF3 | Hepatocellular carcinoma | Knockout and overexpression in liver cancer lines |
| FIGNL1 | Meiotic recombination defects | Knockout in germ cell models |
| TOP2A/TOP2B | Chromatin folding and genome stability | Point mutation and knock-in models |
Autoimmunity and regulatory T cell dysfunction
An autoimmune transcriptional circuit drives FOXP3-positive regulatory T cell dysfunction, implicating altered chromatin binding in the breakdown of immune tolerance. In this context, positive regulation of chromatin binding may be rewired to favor pro-inflammatory gene programs, making it a candidate mechanism for autoimmune pathology.
Cancer and oncogenic chromatin remodeling
Integrative ATAC-seq and RNA-seq analysis has identified PRPF3 as a novel oncogene in hepatocellular carcinoma, linking chromatin accessibility and transcriptional regulation to liver cancer. Positive regulation of chromatin binding can therefore contribute to oncogenic gene expression programs, and its components represent potential therapeutic targets.
Neuroendocrine stress susceptibility
The chromatin-binding protein PHF6 regulates stress susceptibility in the pituitary intermediate lobe, suggesting that positive regulation of chromatin binding influences neuroendocrine responses to stress. This connection broadens the disease relevance of GO:0035563 beyond immunology and oncology.
Genome instability and meiotic defects
FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading, indicating that dysregulated chromatin binding can cause recombination defects. Such defects may contribute to infertility and genome instability syndromes.
From positive regulation of chromatin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce chromatin binding? | CRISPR knockout cell line followed by ATAC-seq |
| Does a specific residue control chromatin association? | Point-mutation knock-in cell line |
| Can a tagged protein report locus-specific binding? | Tagged knock-in with TurboCas |
| Does overexpression increase chromatin occupancy? | Overexpression cell model with RNA-seq |
| Which factors bind a specific locus? | Locus-specific proteomics with TurboCas |
| Does a chromatin regulator affect T cell state? | Primary T cell knockout or overexpression |
How to Study the positive regulation of chromatin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ATAC-seq | Chromatin accessibility | Identify regions with increased binding potential |
| RNA-seq | Transcriptional output | Link chromatin changes to gene expression |
| TurboCas | Locus-specific protein interactome | Capture factors recruited to a genomic region |
| ChIP-seq | Protein-DNA binding genome-wide | Map transcription factor occupancy |
| Hi-C / topology assays | 3D chromatin folding | Assess structural constraints on binding |
| CRISPR knockout | Loss-of-function phenotype | Test causal requirement for chromatin binding |
| CRISPR knock-in | Tagged or mutant protein expression | Track binding dynamics at endogenous loci |
| Proteomics | Protein abundance and interactions | Identify chromatin-associated complexes |
ATAC-seq and RNA-seq integration
Assay for Transposase-Accessible Chromatin with sequencing (ATAC-seq) measures chromatin accessibility, while RNA-seq measures transcriptional output. Integrative analysis of these datasets has been used to identify PRPF3 as a novel oncogene in hepatocellular carcinoma, demonstrating how positive regulation of chromatin binding can be inferred from multi-omic data.
Locus-specific proteomics
TurboCas enables locus-specific labeling of genomic regions and isolation of their associated protein interactome, providing a direct readout of which proteins bind a given chromatin region. This method is particularly powerful for studying positive regulation of chromatin binding because it captures increases in factor recruitment at defined loci.
Chromatin topology assays
Type II topoisomerases shape multi-scale 3D chromatin folding in regions of positive supercoils, and assays that measure chromatin topology can reveal how structural changes influence binding. Such approaches complement accessibility and proteomic methods.
Functional perturbation with CRISPR
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of candidate regulators. For example, FIGNL1-FIRRM function in meiotic recombination has been dissected using genetic perturbation, revealing its role in preventing inappropriate RAD51 and DMC1 loading. Similar strategies can be applied to any gene hypothesized to positively regulate chromatin binding.
How CRISPR Can Be Used to Study GO:0035563 positive regulation of chromatin binding
Knockout
CRISPR knockout is used to delete candidate regulators of chromatin binding and measure the consequences on accessibility, transcription and locus-specific factor recruitment. For example, knocking out FIGNL1 or FIRRM disrupts meiotic recombination and leads to inappropriate RAD51 and DMC1 loading, demonstrating a causal role in controlling chromatin binding. Knockout models are also valuable for testing oncogenes such as PRPF3 in hepatocellular carcinoma.
Point Mutation
Point mutation models allow precise testing of residues that control chromatin association. By introducing specific amino acid substitutions, researchers can determine whether a domain or modification site is required for positive regulation of chromatin binding. Such approaches are complementary to locus-specific proteomics methods like TurboCas, which can reveal whether a mutation alters the protein interactome at a target region.
Knock-in
Knock-in models enable tagging of endogenous proteins with epitopes or proximity-labeling enzymes, facilitating locus-specific labeling and interactome capture. TurboCas is an example of a knock-in-compatible method for labeling genomic regions and isolating associated proteins. Knock-in can also be used to express disease-relevant mutants under endogenous regulatory control.
Overexpression
Overexpression models test whether increasing the abundance of a candidate factor is sufficient to enhance chromatin binding and downstream transcriptional programs. This is particularly useful for oncogenes such as PRPF3, where overexpression can be combined with ATAC-seq and RNA-seq to detect increased chromatin accessibility and target gene activation. Overexpression of chromatin-binding proteins like PHF6 can also reveal effects on stress responses.
How EDITGENE Supports positive regulation of chromatin binding Research
Researchers studying positive regulation of chromatin binding-related genes often need to determine whether a candidate gene is causally involved in increasing chromatin association, and which domains or residues mediate this effect. EDITGENE provides the CRISPR tools and bioinformatics support to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of chromatin binding research.
Frequently Asked Questions About positive regulation of chromatin binding
What is GO:0035563 positive regulation of chromatin binding?
GO:0035563 is a biological process term describing any process that increases the frequency, rate or extent of chromatin binding, where chromatin binding is the selective interaction with the DNA-protein-RNA fiber network of interphase chromosomes.
What genes are involved in positive regulation of chromatin binding?
Genes implicated in related processes include FOXP3, PHF6, RUNX3, PRPF3, TOP2A, TOP2B, FIGNL1 and FIRRM, based on studies of autoimmunity, stress susceptibility, T cell residency, cancer and meiosis.
How is positive regulation of chromatin binding measured?
It can be measured using ATAC-seq, RNA-seq, ChIP-seq, locus-specific proteomics such as TurboCas, and chromatin topology assays.
Why is positive regulation of chromatin binding important in disease?
Dysregulation of chromatin binding is linked to autoimmune regulatory T cell dysfunction, hepatocellular carcinoma, neuroendocrine stress susceptibility and meiotic recombination defects.
What is the role of PHF6 in chromatin binding?
PHF6 is a chromatin-binding protein that regulates stress susceptibility in the pituitary intermediate lobe.
How do type II topoisomerases affect chromatin binding?
Type II topoisomerases shape multi-scale 3D chromatin folding in regions of positive supercoils, which can influence how factors access and bind chromatin.
Can CRISPR be used to study positive regulation of chromatin binding?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of candidate regulators, and CRISPR library screening enables unbiased discovery.
What is TurboCas and how does it relate to chromatin binding?
TurboCas is a method for locus-specific labeling of genomic regions and isolating their associated protein interactome, providing a direct readout of chromatin binding at defined loci.
Which diseases are associated with altered chromatin binding?
Autoimmune diseases, hepatocellular carcinoma, neuroendocrine stress-related conditions and meiotic defects have been associated with altered chromatin binding processes.
How does RUNX3 regulate chromatin binding in T cells?
RUNX3 programs CD8-positive T cell residency in non-lymphoid tissues and tumors by shaping chromatin interactions.
Conclusion
GO:0035563 positive regulation of chromatin binding is a fundamental biological process that governs how factors engage the genome during interphase. Its mechanisms span pioneer factor activity, chromatin topology, locus-specific protein assembly and integration with transcription and genome stability. Dysregulation of this process contributes to autoimmunity, cancer, neuroendocrine stress responses and meiotic defects, making it a high-value area for mechanistic and translational research. By combining CRISPR-based perturbation with multi-omic and locus-specific proteomic methods, researchers can move from correlation to causation and identify actionable targets. EDITGENE supports this workflow with knockout, point-mutation, knock-in, overexpression, library screening and bioinformatics services tailored to chromatin binding research.
References
- 1. Sumida TS et al.. 2024. An autoimmune transcriptional circuit drives FOXP3(+) regulatory T cell dysfunction.. Sci Transl Med 16(762):eadp1720 PMID: 39196959
- 2. Liu B et al.. 2026. Regulation of stress susceptibility by chromatin-binding protein PHF6 in the pituitary intermediate lobe.. Mol Psychiatry 31(3):1665-1680 PMID: 41053436
- 3. Milner JJ et al.. 2017. Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours.. Nature 552(7684):253-257 PMID: 29211713
- 4. Cenik BK et al.. 2024. TurboCas: A method for locus-specific labeling of genomic regions and isolating their associated protein interactome.. Mol Cell 84(24):4929-4944.e8 PMID: 39706164
- 5. Bai Y et al.. 2024. Integrative analysis based on ATAC-seq and RNA-seq reveals a novel oncogene PRPF3 in hepatocellular carcinoma.. Clin Epigenetics 16(1):154 PMID: 39501301
- 6. Longo GMC et al.. 2024. Type II topoisomerases shape multi-scale 3D chromatin folding in regions of positive supercoils.. Mol Cell 84(22):4267-4281.e8 PMID: 39486417
- 7. Marasca F et al.. 2022. LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion.. Nat Genet 54(2):180-193 PMID: 35039641
- 8. Zainu A et al.. 2024. FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading.. Nat Commun 15(1):7015 PMID: 39147779
